United Therapeutics (NSDQ:UTHR) said today that it stepped closer to completing its $216 million acquisition of SteadyMed (NSDQ:STDY) after terminating the the HSR Act waiting period.
The merger combines two companies that were in court as recently as last November, fighting over patents covering treprostinil, the active ingredient in both companies’ lead products.
Read the whole story on our sister site, Drug Delivery Business News
The post United Therapeutics $216m deal for SteadyMed clears HRS Act waiting period appeared first on MassDevice.